Clinical studies have shown that adjuvant therapy with quercetin in early COVID-19 patients significantly reduced the release of proinflammatory factors, such as TNF-β and IL-1β, and alleviated inflammation in patients with COVID-19 [43]. This evidence concerns the gene IL1B and COVID-19.